HER2 and LA/mUC: A Multi-country Chart Review Cohort Study - Trial NCT05902494
Access comprehensive clinical trial information for NCT05902494 through Pure Global AI's free database. This phase not specified trial is sponsored by Seagen Inc. and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Seagen Inc.
Timeline & Enrollment
N/A
Jun 29, 2023
Feb 29, 2024
Primary Outcome
Real-world Objective Response Rate (rwORR) per modified response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)
Summary
This study is being done to learn about urothelial cancers that make HER2 and how that
 affects treatment choices for participants with urothelial cancer. During this study, the
 medical and health records of participants will be reviewed to learn more about their health.
 
 Participants will have urothelial cancer that has grown in the body near where it started
 (locally advanced) and cannot be removed (unresectable) or has spread through the body
 (metastatic).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05902494
Non-Device Trial